osimertinib

Oncologist and researcher Yan Leyfman reported real-world data on outcomes after first-line osimertinib treatment in patients with EGFR-mutated non-small cell lung cancer. The presentation highlights how the targeted therapy performs outside clinical trial settings, a topic of interest to oncologists tracking effectiveness and resistance patterns in routine care.